Clarametyx Home Revenue and Competitors

Location

#1057

Growjo Ranking

Fintech

Industry

Estimated Revenue & Valuation

  • Clarametyx Home's estimated annual revenue is currently $1.8M per year.(i)
  • Clarametyx Home's estimated revenue per employee is $91,000

Employee Data

  • Clarametyx Home has 20 Employees.(i)
  • Clarametyx Home grew their employee count by 5% last year.

Clarametyx Home's People

NameTitleEmail/Phone
1
Co-founder & Chief Scientific OfficerReveal Email/Phone
2
Co-founder & Board Co-ChairReveal Email/Phone
3
CEOReveal Email/Phone
4
VP, Clinical OperationsReveal Email/Phone
5
Director Clinical Development and Portfolio StrategyReveal Email/Phone
6
Co-founder & Chief Scientific OfficerReveal Email/Phone
7
Director, Project OperationsReveal Email/Phone
8
Chief Operating OfficerReveal Email/Phone
9
Operations Program ManagerReveal Email/Phone
10
Scientific Co-Founder & Scientific Advisory Board Co-ChairReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0M1-67%$3MN/A
#2
$379.7M0N/A$30.5MN/A
#3
$6.2M55-4%$3.4MN/A
#4
$0.6M9-10%N/AN/A
#5
$62.7M380-29%$609.1MN/A
#6
$0M20%$10MN/A
#7
$56.2M346-7%N/AN/A
#8
$11.4M88N/AN/AN/A
#9
$94.6M5825%N/AN/A
#10
$3.8M37-7%N/AN/A
Add Company

What Is Clarametyx Home?

Clarametyx Biosciences Inc. is a preclinical stage biotechnology company developing immune-enabling biologic therapies to fight life-threatening infections. Our novel technology platform targets the protective barrier around bacteria, known as biofilms.

keywords:N/A

N/A

Total Funding

20

Number of Employees

$1.8M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Clarametyx Home News

2022-03-30 - CARB-X Awards Clarametyx Biosciences $3.89 Million in ...

(“Clarametyx”), a preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter serious infections...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2M20N/AN/A
#2
$2.1M2011%N/A
#3
$3.5M205%N/A
#4
$2M20-5%N/A
#5
$3.5M205%N/A